Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 11, 1997

View Archived Issues

Takeda reports MIP-1alpha/RANTES receptor antagonists

New hydroxamic acid compounds inhibiting TNF, PDE IV and/or MMPs

SKB patents several series of vitronectin receptor antagonists

New opioid analgesics from Astra

New atypical antipsychotic agent from HMR

YM-60828: an orally active factor Xa inhibitor from Yamanouchi

Novartis launches Exelon

Topical foscarnet for treatment of herpes labialis

MiniMed and LRX combine forces for pulmonary hypertension treatment

AMO Array Multifocal IOL approved for marketing in U.S.

PharmaPrint begins phase II trial of herbal treatment for BPH

Lark signs DNA sequencing agreement with ZymoGenetics

Expanded uses of LifeCell's AlloDerm discussed at recent meeting

Geron awarded SBIR grant for development of telomerase-based diagnostics

IDEC licenses rights to novel antiinflammatory technology

Promising initial results reported for VasoCare therapy in Raynaud's disease

Final phase I/IIa data reported on oral Panretin in APL

Oxygent enhances oxygenation more effectively than blood in surgical patients

Meridian's rapid test for rotavirus approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...